Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 2;31(5):1117–1122. doi: 10.1038/leu.2016.316

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Comparison of platelet function in ibrutinib-treated CLL (n=64), ibrutinib-treated mantle cell lymphoma (MCL; n=7), CC292-treated CLL (n=6), CLL control (n=13) and X-linked agammaglobulinemia (XLA; n=1) patients. Median RIPA values: ibrutinib/CLL (19.5 U, range: 0–199 U), ibrutinib/MCL (20.5 U, range: 9–97 U), CC292/CLL (23 U, range: 3–49 U), Control CLL (37 U, range: 6–94 U) and XLA (56 U, range 33–79 U).